ATRA missed EPS expectations by 48.64%
Nov 12, 2024, 11:31 PM
0.00%
What does ATRA do
Atara Biotherapeutics, headquartered in Thousand Oaks, California, is a biotechnology company specializing in allogeneic T-cell immunotherapy, with products like Ebvallo and ATA3219 in various development stages. The company went public on October 16, 2014, and employs 173 staff.
Atara Biotherapeutics (ATRA) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Atara Biotherapeutics's actual EPS was -$2.93, missing the estimate of -$1.97 per share, resulting in a -48.64% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.